Avera Dialysis - Brookings is a medicare approved dialysis facility center in Brookings, South Dakota and it has 7 dialysis stations. It is located in Brookings county at 300 22nd Ave Ste 101, Brookings, SD, 57006. You can reach out to the office of Avera Dialysis - Brookings at (605) 696-7760. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Avera Dialysis - Brookings has the following ownership type - Non-Profit. It was first certified by medicare in September, 2012. The medicare id for this facility is 433510 and it accepts patients under medicare ESRD program.
| Name | Avera Dialysis - Brookings |
|---|---|
| Location | 300 22nd Ave Ste 101, Brookings, South Dakota |
| No. of Dialysis Stations | 7 |
| Medicare ID | 433510 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 300 22nd Ave Ste 101, Brookings, South Dakota, 57006 | |
| (605) 696-7760 | |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago
| NPI Number | 1710923172 |
| Doing Business As | Prairie Lakes Healthcare System Inc. |
| Address | 300 22nd Ave Brookings, South Dakota, 57006 |
| Phone Number | (605) 882-7000 |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago
| NPI Number | 1891055174 |
| Organization Name | Avera Dialysis Brookings |
| Doing Business As | Avera Mckennan |
| Address | 300 22nd Ave Brookings, South Dakota, 57006 |
| Phone Number | (605) 696-7760 |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 13 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 8 |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 21 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 170 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Avera Dialysis - Brookings with elevated calcium levels.
| Patients with hypercalcemia | 22 |
| Hypercalcemia patient months | 182 |
| Patients with Serumphosphor | 23 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 51 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 12 |
| Patients with Serumphosphor greater than 7 mg/dL | 7 |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 22 |
| Patient months included in arterial venous fistula and catheter summaries | 153 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 51 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 18 |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 21 |
| Hospitalization Rate in facility | 113.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 330.5 |
| Hospitalization Rate: Lower Confidence Limit | 42.7 |
News Archive
The National Council on Disability (NCD) will release a report on workforce infrastructure for people with disabilities at the JW Marriott Houston, 5150 Westheimer, Houston, TX, from 9:15 a.m. until 10:15 a.m. on Wednesday, January 20, 2010.
The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.
Some adults and children with acute leukemia could benefit from certain transplants of blood stem cells, but the benefits are not equal across all cases of leukemia, according to a new review of 15 studies.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 5 days ago